Sponsored by
VBI-1901 is a vaccine that uses enveloped virus like particle (eVLP) technology to target two cytomegalovirus (CMV) antigens - gB and pp65. In the Phase 1/2a study for recurrent glioblastoma (n=16 patients), median overall survival was 12.9 months; patients who achieved a partial tumor response or stable disease (7/16) all reached a minimum survival of 12 months, and 1 patient survived at least 40 months. The Phase 2b trial is still in early stages, but 3/7 patients treated with the vaccine so far have achieved disease control (stable disease or partial response). We hope to see additional interim data reported by the end of this year.